Eli Lilly and Company $LLY Shares Sold by Symphony Financial Ltd. Co.

Symphony Financial Ltd. Co. decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 63.6% in the 3rd quarter, Holdings Channel reports. The firm owned 6,202 shares of the company’s stock after selling 10,824 shares during the period. Symphony Financial Ltd. Co.’s holdings in Eli Lilly and Company were worth $4,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mn Services Vermogensbeheer B.V. increased its position in Eli Lilly and Company by 1.4% in the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 305,688 shares of the company’s stock valued at $233,240,000 after acquiring an additional 4,300 shares during the period. Coordinated Financial Services Inc. grew its stake in shares of Eli Lilly and Company by 82.8% in the 3rd quarter. Coordinated Financial Services Inc. now owns 532 shares of the company’s stock valued at $406,000 after purchasing an additional 241 shares during the last quarter. Dash Acquisitions Inc. increased its holdings in shares of Eli Lilly and Company by 207.0% in the third quarter. Dash Acquisitions Inc. now owns 1,489 shares of the company’s stock valued at $1,211,000 after purchasing an additional 1,004 shares during the period. Birch Financial Group LLC raised its stake in shares of Eli Lilly and Company by 18.9% during the third quarter. Birch Financial Group LLC now owns 1,425 shares of the company’s stock worth $1,087,000 after purchasing an additional 227 shares during the last quarter. Finally, UniSuper Management Pty Ltd lifted its holdings in shares of Eli Lilly and Company by 13.8% during the third quarter. UniSuper Management Pty Ltd now owns 164,787 shares of the company’s stock worth $125,732,000 after purchasing an additional 19,987 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 2.1%

Eli Lilly and Company stock opened at $1,065.05 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The firm has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.11, a price-to-earnings-growth ratio of 0.82 and a beta of 0.35. The stock’s fifty day moving average is $1,057.19 and its two-hundred day moving average is $880.07. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bernstein raised conviction on LLY, projecting a $1,300 target on expectations that Lilly’s weight‑loss pill will be a blockbuster — this supports upside and keeps buy-side interest alive. Bernstein Sees Eli Lilly Stock (LLY) Hitting $1,300 Per Share
• Positive Sentiment: Pipeline progress: Lilly reported advancement of early‑stage LY4064809, signaling continued R&D momentum that can de‑risk future growth beyond GLP‑1s. Eli Lilly Advances Early-Stage LY4064809 Study
• Positive Sentiment: Device/delivery gains: Lilly completed a device study for remternetug delivery options — positive for convenience/uptake and formulary discussions. Eli Lilly Advances Remternetug Delivery Options With Completed Device Study
• Positive Sentiment: Late‑stage obesity program: Lilly launched a Phase 3b dosing study for retatrutide, which, if successful, strengthens near‑term growth visibility in obesity. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Oncology tailwind: Analyst pieces highlight Verzenio and new oncology launches as incremental revenue drivers that broaden the story beyond GLP‑1s. Here’s How Eli Lilly’s Oncology Drugs Are Poised Ahead of Q4 Earnings
• Neutral Sentiment: Industry outlook: Executives at JPMorgan H.C. said the obesity market will expand into more pills, combos and easier access — a market‑wide constructive view but it raises competitive and margin questions. What obesity drugmakers see next in the market
• Neutral Sentiment: Corporate moves: Lilly named Pranav Shroff director of marketing — a routine leadership update with limited near‑term financial impact. Eli Lilly appoints Pranav Shroff as director of marketing
• Negative Sentiment: Critical take: Opinion pieces urge investors to consider alternatives to Lilly, arguing the stock’s high valuation is driven largely by GLP‑1 enthusiasm — this kind of narrative can trigger profit‑taking. Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
• Negative Sentiment: Competition risk: Sun Pharma won a Wegovy generic nod in India, setting up tougher pricing/market dynamics in a key growth market for obesity drugs. Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market
• Negative Sentiment: Regulatory/legal headline: Coverage of a lawsuit over insulin pricing keeps regulatory and reputational risk in focus for investors. Rokita Discusses Lawsuit Against Eli Lilly & Insulin Prices

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. Guggenheim cut their price objective on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating for the company in a research report on Tuesday. HSBC reissued a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Morgan Stanley increased their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Finally, JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Buy” and a consensus price target of $1,174.61.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.